W17--Financial Toxicity in CF Care

Chair(s)

• 

  Gregory Sawicki, MD, MPH (he/him/his)

  Cystic Fibrosis Center
  Boston Children's Hospital
• 

  Jamie Wooldridge, MD (she/her/hers)

  University of Rochester Medical Center

This workshop will include a set of presentations describing the financial and cost burdens faced by people with CF, including impacts on quality of life and health care utilization. In addition, the session will explore challenges and facilitators for clinicians and care teams to evaluate and address financial burden in CF, as well as explore the impact of CFTR modulator therapy on financial outcomes in CF.

Presentations:

• 7:45 AM – 9:45 AM ET

  COST-CF: Exploring financial stressors on daily life and access to care within the CF community
  

  Speaker: Aricca D. Van Citters, MS – Geisel School of Medicine at Dartmouth
• 7:45 AM – 9:45 AM ET

  W17.2- Impact of CFTR modulator (CFTR-M) therapy on basic life needs and financial concerns in people with cystic fibrosis (PwCF): Data from the Well-ME Survey
  

  Speaker: Heather Boas, MD (she/her/hers) – Children's Hospital of Philadelphia
• 7:45 AM – 9:45 AM ET

  W17.3- Clinician perspectives and practices related to cost of care discussions among people with cystic fibrosis
  

  Speaker: Ryan C. Perkins, MD MPH – Boston Children’s Hospital/Brigham & Women’s Hospital
• 7:45 AM – 9:45 AM ET

  W17.4- The next step – Identification of financial vulnerabilities for people with cystic fibrosis and a framework for intervention
  

  Speaker: Karen R. Carey, CRS (she/her/hers) – Cystic Fibrosis Foundation
• 7:45 AM – 9:45 AM ET

  W17.5- Research and development expenditure for CFTR modulators versus revenues after marketing: Striking the balance?
  

  Speaker: Jonathan Guo, MBBS, BSc (he/him/his) – Imperial College London